Lucas Arruda
Chief Scientific Officer CuraCell Holding
Seminars
Wednesday 18th November 2026
Advancing TIL Clinical Development by Generating Early Efficacy Signals in Cold Solid Tumors
9:00 am
- Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
- Exploring patient selection and tumor sourcing challenges in low immunogenic indications
- Translating early treatment experience into future trial design decisions
